Myeloperoxidase (MPO) and eosinophil peroxidase (EPO) enzymes work
to preferentially kill a broad range of pathogens through a unique
mechanism of action unlikely to induce resistance. more
Microbiological infection caused by bacteria, viruses, fungi, and prions is an important concern in a range of healthcare sectors affecting human health and well-being. Safe and effective microbicidal products are especially critical today, when antimicrobial resistance and the potential for the rapid spread of pathogens have become public-health issues in countries throughout the world.
For 20 years, Exoxemis, Inc. has been the leader in the development of broad-spectrum haloperoxidase-based products for use in high-value product areas, including a biological entity for use in high morbidity/mortality applications. We are committed to integrating our technology with the intellectual, financial, and commercial strengths of prospective partners to develop innovative products and long-term relationships.
Surgical Infection News
Are new threats emerging beyond MRSA?
An article appearing recently in The New York Times discusses gram-negative bacteria, such as Acinetobacter baumannii, that are beginning to exhibit antimicrobial resistance in hospital and community settings. Learn more >>